Specificities of lung adenocarcinoma in women who have never smoked

Journal of Thoracic Oncology

Volumn 8, Issue 7, 2013, Pages 923-929

  Mazières, Julien ^a,i   Rouquette, Isabelle ^b   Lepage, Benoit ^c   Milia, Julie ^a   Brouchet, Laurent ^c   Guibert, Nicolas ^a   Beau Faller, Michèle ^d   Validire, Pierre ^e   Hofman, Paul ^f   Fouret, Pierre ^g,h  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CHU RANGUEIL   (France)

^c SERVICE DE PNEUMOLOGIE   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e INSTITUT MUTUALISTE MONTSOURIS   (France)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h INSERM   (France)

ⁱ Service de Pneumologie et Soins Intensifs   (France)

Author keywords

Epidermal growth factor receptor; Estrogen receptor; K Ras; Non small cell lung cancer; Tobacco

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; K RAS PROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC TRAIT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; TOBACCO;

EID: 84880917733     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182904dfb     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Quoix E, Mennecier B, [Lung cancer in women]. Rev Mal Respir, 2005. 22(6 Pt 2): 8S55-62.
3. Mazières J, Rouquette I, Brouchet L. [Lung cancer in women and pregnancy: towards a hormonal origin?]. Rev Mal Respir 2007;24:983-997.
4. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
5. Cadranel J, Zalcman G, Sequist L. Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. Eur Respir J 2011;37:183-193.
6. Siegfried JM, Hershberger PA, Stabile LP. Estrogen receptor signaling in lung cancer. Semin Oncol 2009;36:524-531.
7. Rosell R, Moran T, Queralt C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
8. Márquez-Garbán DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007;72:135-143.
9. Rouquette I, Lauwers-Cances V, Allera C, et al. Characteristics of lung cancer in women: importance of hormonal and growth factors. Lung Cancer 2012;76:280-285.
10. Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002;62:2141-2150.
11. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005;65:1459-1470.
12. Nose N, Sugio K, Oyama T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009;27:411-417.
13. Raso MG, Behrens C, Herynk MH, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009;15:5359-5368.
14. Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol 2012;7:485-495.
15. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:561-570.
16. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-790.
17. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25:472-478.
18. Job B, Bernheim A, Beau-Faller M, et al.; LG Investigators. Genomic aberrations in lung adenocarcinoma in never smokers. PLoS ONE 2010;5:e15145.
19. Toh CK, Lim WT. Lung cancer in never-smokers. J Clin Pathol 2007;60:337-340.
20. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
21. Groome PA, Bolejack V, Crowley JJ, et al.; IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
22. Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005;11:5084-5089.
23. Alì G, Donati V, Loggini B, et al. Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 2008;39:1465-1473.
24. Barnes DM, Millis RR, Gillett CE, et al. The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients. Endocr Relat Cancer 2004;11:85-96.
25. Nagy-Mignotte H, Guillem P, Vesin A, et al.; Multidisciplinary Thoracic Oncology Group at Grenoble University Hospital. Primary lung adenocarcinoma: characteristics by smoking habit and sex. Eur Respir J 2011;38:1412-1419.
26. D'Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29:2066-2070.
27. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers-a review. Eur J Cancer 2012;48:1299-1311.
28. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
29. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011;223:219-229.
30. Garon EB, Pietras RJ, Finn RS, et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol 2013;8:270-278.
31. Traynor AM, Schiller JH, Stabile LP, et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009;64:51-59.